DDX17 and non-small cell lung carcinoma: Compared with NSCLC cells that are sensitive to gefitinib, DDX17 expression in gefitinib-resistant cells is increased, and the Wnt/β-catenin signaling pathway is activated to ultimately render NSCLC cells resistant to gefitinib (14).